Skip to main content

Generalised Myasthenia Gravis

Red laboratory rack holding multiple small, labeled test tubes with caps, arranged in neat rows, suggesting a scientific setting.

We are committed to meeting the needs of people with generalised myasthenia gravis (gMG) by exploring new approaches for rare neurological diseases.

Challenge

Generalised myasthenia gravis (gMG) is a rare, chronic, autoimmune disease that breaks down the communication between nerves and muscles, leading to muscle weakness that worsens with exertion and improves with rest. It is most common in women below their 40s and men over 60 years old. 

People with gMG may experience any of the following core symptoms: ocular symptoms (drooping eyelids, double vision),  difficulties with facial expression, chewing and swallowing, speaking,  weakness of the arms,  legs and neck resulting in limited mobility, shortness of breath, and in most extreme cases, respiratory failure (myasthenic crisis). Often diagnosis of people with gMG is delayed by months, or even years, due to the varying nature of symptoms and overlapping symptoms with other conditions.

The majority of people with gMG do not achieve stable remission with currently available treatments.

Focus

At Roche, we are exploring new approaches to meet the needs of people living with chronic, rare neurological diseases like gMG.

Downloads

Download Understanding Generalised Myasthenia Gravis (gMG)

PDF

Discover more

  • Rare disease

    Pharma | Diagnostics

    Working together to build a better world for people with rare diseases.

  • Neuromyelitis optica spectrum disorder (NMOSD)

    Solutions

    Through medical innovation and partnerships, we are providing new options to people living with neuromyelitis optica spectrum disorder (NMOSD) to help them retain as much independence as possible.

  • Multiple Sclerosis

    Solutions

    We’re committed to advancing the clinical understanding of underlying disease activity and progression for the millions of people living with multiple sclerosis (MS) worldwide.